Περίληψη:
OBJECTIVES: COVID-19 has evolved into a global health crisis, variably affecting the management of patients with chronic illnesses. Patients with inflammatory bowel disease (IBD) may represent a vulnerable population due to frequent administration of immune-modifying treatments. We aimed to depict the natural history of COVID-19 infection in Greek patients with IBD at a nationwide level via unbiased reporting of all cases that were registered during the sequential waves of the pandemic. METHODS: Following a national call from the Hellenic Society for the study of IBD, we enrolled all IBD patients with established diagnoses of COVID-19. Clinical and epidemiological data, including COVID-19 modifying factors and IBD-associated therapies, were analyzed against adverse outcomes (hospitalization, ICU admission and death). RESULTS: We identified 154 IBD patients who were diagnosed with COVID-19 (men: 58.4%; mean age=41.7 years [SD = 14.9]; CD: 64.3%). Adverse outcomes were reported in 34 patients (22.1%), including 3 ICU admissions (1.9%) and two deaths (1.3%). Multivariate logistic regression analysis showed that age (OR = 1.04, 95% CI, 1-1.08) and dyspnea at presentation (OR = 7.36, 95% CI, 1.84-29.46) were associated with worse outcomes of COVID-19 infection. In contrast, treatment with biologics, in particular anti-TNF agents, exerted a protective effect against an unfavorable COVID-19 disease course (OR = 0.4, 95% CI, 0.16-0.99). Patients on subcutaneous biologics were more likely to halt treatment due to the infection as compared to those on intravenous biologics. CONCLUSIONS: IBD patients who developed COVID-19 had a benign course with adverse outcomes being infrequent. Treatment with anti-TNF biologics had a protective effect, thus, supporting continuation of therapy during the pandemic. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Συγγραφείς:
Bamias, G.
Kokkotis, G.
Christidou, A.
Christodoulou, D.K.
Delis, V.
Diamantopoulou, G.
Fessatou, S.
Gatopoulou, A.
Giouleme, O.
Kafritsa, P.
Kalantzis, C.
Kapsoritakis, A.
Karatzas, P.
Karmiris, K.
Katsanos, K.
Kevrekidou, P.
Kosmidis, C.
Mantaka, A.
Mathou, N.
Michalopoulos, G.
Michopoulos, S.
Papaconstantinou, I.
Papatheodoridis, G.
Polymeros, D.
Potamianos, S.
Poulopoulos, G.
Protopapas, A.
Sklavaina, M.
Soufleris, K.
Theocharis, G.
Theodoropoulou, A.
Triantafillidis, J.K.
Triantafyllou, K.
Tsiolakidou, G.
Tsironi, E.
Tzouvala, M.
Viazis, N.
Xourgias, V.
Zacharopoulou, E.
Zampeli, E.
Mantzaris, G.J.
Λέξεις-κλειδιά:
tumor necrosis factor inhibitor, adult; chronic disease; human; inflammatory bowel disease; male, Adult; Chronic Disease; COVID-19; Humans; Inflammatory Bowel Diseases; Male; SARS-CoV-2; Tumor Necrosis Factor Inhibitors
